Evolocumab’s Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-021-00480-y
Abstract: The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 inhibition in Subjects with Elevated Risk) trial was conducted to study cardiovascular outcomes of treatment with evolocumab. The trial was terminated after a median follow-up of 2.2… read more here.
Keywords: risk; long term; mortality; evolocumab long ... See more keywords